前列腺癌的早期诊断研究进展

闫厚煜; 邢金春; 张开颜; 王涛; 白培德

doi:10.13201/j.issn.1001-1420.2020.03.018

前列腺癌的早期诊断研究进展

- 厦门大学附属第一医院泌尿外科(福建厦门, 361000)
基金项目:
2017年福建省科技计划项目(No:2017D0010)

2017年福建省卫生计生中青年骨干人才培养项目(No:2017-ZQN-81)

详细信息

通讯作者: 白培德,E-mail:baipeide@126.com

中图分类号: R737.25

收稿日期: 2018-07-08

Advances in early diagnosis of prostate cancer

- Department of Urology, First Affiliated Hospital of Xiamen University, Xiamen, Fujian, 361000, China

More Information

Corresponding author: BAI Peide, E-mail: baipeide@126.com

Received Date: 08 July 2018

摘要

摘要: 前列腺癌(prostate cancer,PCa)是好发于老年男性恶性肿瘤之一,占男性恶性肿瘤发病率的第2位,死亡率的第6位。而PCa的疾病预后与其早期诊断密切相关。近年来,关于PCa的早期筛查与诊断的多有研究,但具体并未予以一个完全统一的共识。故本文将从多方面PCa的筛查指标及辅助检查作一综述,以指导PCa的早期筛查与诊断。
- 前列腺癌 /
- 肿瘤标志物 /
- 早期筛查 /
- Gleason评分
Abstract: Prostate cancer is one of the most common malignancies in oldmales, it accounts for the secondhighest incidence of all the male malignancies and the sixth highest in mortality. The prognosis of prostate cancer is closely related to its early screening. Recently, many researches about early screening and diagnosis of prostate cancer have been established. However, there is no consensus on a complete reunification. Therefore, this article mainly summarizes the screening indicators and auxiliary examinations of prostate cancer from many aspects, in order to guide the early screening and diagnosis of prostate cancer.
- prostate cancer /
- tumor marker /
- early screening /
- Gleason scores

HTML全文

参考文献(39)

[1]	Killick E,Bancroft E,Kote-Jarai Z,et al.Beyond prostate-specific antigen-future biomarkers for the early detection and management of prostate cancer[J].Clin Oncol(R Coll Radiol),2012,24(8):545-55.
[2]	Queisser A,Hagedorn SA,Braun M,et al.Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer[J].Mod Pathol,2015,28(1):138-145.
[3]	王祺,李彦锋,江军,等.PCa诊断中f/tPSA比值在灰区外的应用价值研究[J].临床泌尿外科杂志,2016,31(9):787-792.
[4]	林毅,李黎明,强万明,等.游离与总PSA比值检测在前列腺癌诊断中的作用[J].中华泌尿外科杂志,2003,24(4):287-287.
[5]	Feng ZJ,Xue C,Wen JM,et al.PSAD Test in the Diagnosis of Prostate Cancer:a Meta-Analysis[J].Clin Lab,2017,63(1):147-155.
[6]	Liu M,Hou HM,Li X,et al.Value of prostate volume,PSAD and F/T in the detection of prostate cancer in males with PSA 4-10 mug/L[J].Zhonghua Zhong Liu Za Zhi,2016,38(7):526-529.
[7]	Lujan M,Paez A,Llanes L,et al.Prostate specific antigen density.Is there a role for this parameter when screening for prostate cancer?[J].Prostate Cancer Prostatic Dis,2001,4(3):146-149.
[8]	Carter HB,Pearson JD,Metter EJ,et al.Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease[J].Jama,1992,267(16):2215-2220.
[9]	Carter HB,Ferrucci L,Kettermann A,et al.Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability[J].J Natl Cancer Inst,2006,98(21):1521-1527.
[10]	O'brien MF,Cronin AM,Fearn PA,et al.Pretreatment prostate-specific antigen(PSA)velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy[J].J Clin Oncol,2009,27(22):3591-3597.
[11]	Vickers A,Cronin A,Roobol M,et al.Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel:an independent replication[J].J Clin Oncol,2010,28(15):2493-2498.
[12]	Bryant RJ,Sjoberg DD,Vickers AJ,et al.Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the Protec T study[J].J Natl Cancer Inst,2015,107(7):djv095.
[13]	Vickers AJ,Gupta A,Savage CJ,et al.A panel of kallikrein marker predicts prostate cancer in a large,population-based cohort followed for 15 years without screening[J].Cancer Epidemiol Biomarkers Prev,2011,20(2):255-261.
[14]	Parekh DJ,Punnen S,Sjoberg DD,et al.A multi-institutional prospective trial in the USA confirms that the 4K score accurately identifies men with high-grade prostate cancer[J].Eur Urol,2015,68(3):464-470.
[15]	Konety B,Zappala SM,Parekh DJ,et al.The 4K score(R)Test Reduces Prostate Biopsy Rates in Community and Academic Urology Practices[J].Rev Urol,2015,17(4):231-240.
[16]	Barinka C,Rojas C,Slusher B,et al.Glutamate carboxypeptidase Ⅱ in diagnosis and treatment of neurologic disorders and prostate cancer[J].Curr Med Chem,2012,19(6):856-870.
[17]	Meller B,Bremmer F,Sahlmann CO,et al.Alterations in androgen deprivation enhanced prostate-specific membrane antigen(PSMA)expression in prostate cancer cells as a target for diagnostics and therapy[J].EJNMMI Res,2015,5(1):66.
[18]	Tsourlakis MC,Klein F,Kluth M,et al.PSMA expression is highly homogenous in primary prostate cancer[J].Appl Immunohistochem Mol Morphol,2015,23(6):449-455.
[19]	陈志强,张志根.PSAM和PSAMR与Gleason评分及临床分期的相关性研究[J].临床泌尿外科杂志,2017,32(3):229-231.
[20]	Shen D,Xie F,Edwards WB.Evaluation of phage display discovered peptides as ligands for prostate-specific membrane antigen(PSMA)[J].PLoS One,2013,8(7):e68339.
[21]	Bachour DM,Chahin E,Al-Fahoum S.Human Kallikrein-2,Prostate Specific Antigen and Free-Prostate Specific Antigen in Combination to Discriminate Prostate Cancer from Benign Diseases in Syrian Patients[J].Asian Pac J Cancer Prev,2015,16(16):7085-7088.
[22]	Shang Z,Niu Y,Cai Q,et al.Human kallikrein 2(KLK2)promotes prostate cancer cell growth via function as a modulator to promote the ARA70-enhanced androgen receptor transactivation[J].Tumour Biol,2014,35(3):1881-1890.
[23]	De La Calle C,Patil D,Wei JT,et al.Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naive Men[J].J Urol,2015,194(1):65-72.
[24]	Stephan C,Vincendeau S,Houlgatte A,et al.Multicenter evaluation of[-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer[J].Clin Chem,2013,59(1):306-314.
[25]	Thorek DL,Evans MJ,Carlsson SV,et al.Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection.Established relevance and emerging roles[J]/Thromb Haemost,2013,110(3):484-492.
[26]	Ezquer A,Ortega Hrescak MC,Sanagua C,et al.Transrectal doppler ultrasound during prostate biopsy:clinical utility and limitations[J].Actas Urol Esp,2015,39(1):13-19.
[27]	Aboumarzouk OM,Ogston S,Huang Z,et al.Diagnostic accuracy of transrectal elastosonography(TRES)imaging for the diagnosis of prostate cancer:a systematic review and meta-analysis[J].BJU Int,2012,110(10):1414-1423.
[28]	Pallwein L,Mitterberger M,Struve P,et al.Comparison of sonoelastography guided biopsy with systematic biopsy:impact on prostate cancer detection[J].Eur Radiol,2007,17(9):2278-2285.
[29]	Siddiqui MM,Rais-Bahrami S,Truong H,et al.Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy[J].Eur Urol,2013,64(5):713-719.
[30]	Sonn GA,Chang E,Natarajan S,et al.Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen[J].Eur Urol,2014,65(4):809-815.
[31]	Lee DJ,Ahmed HU,Moore CM,et al.Multiparametric magnetic resonance imaging in the management and diagnosis of prostate cancer:current applications and strategies[J].Curr Urol Rep,2014,15(3):390.
[32]	Turkbey B,Mani H,Shah V,et al.Multiparametric 3T prostate magnetic resonance imaging to detect cancer:histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds[J].J Urol,2011,186(5):1818-1824.
[33]	Dias JL,Pina JM,Joao R,et al.Prostate Cancer:The Role of Multiparametric Magnetic Resonance Imaging[J].Acta Med Port,2015,28(2):240-249.
[34]	Rakow-Penner RA,White NS,Parsons JK,et al.Novel technique for characterizing prostate cancer utilizing MRI restriction spectrum imaging:proof of principle and initial clinical experience with extraprostatic extension[J].Prostate Cancer Prostatic Dis,2015,18(1):81-85.
[35]	Mccammack KC,Kane CJ,Parsons JK,et al.In vivo prostate cancer detection and grading using restriction spectrum imaging-MRI[J].Prostate Cancer Prostatic Dis,2016,19(2):168-173.
[36]	Epstein JI,Egevad L,Amin MB,et al.The 2014 International Society of Urological Pathology(ISUP)Consensus Conference on Gleason Grading of Prostatic Carcinoma:Definition of Grading Patterns and Proposal for a New Grading System[J].Am J Surg Pathol,2016,40(2):244-252.
[37]	Epstein JI,Zelefsky MJ,Sjoberg DD,et al.A Contemporary Prostate Cancer Grading System:A Validated Alternative to the Gleason Score[J].Eur Urol,2016,69(3):428-435.
[38]	Rubin MA,Girelli G,Demichelis F.Genomic Correlates to the Newly Proposed Grading Prognostic Groups for Prostate Cancer[J].Eur Urol,2016,69(4):557-560.
[39]	Loeb S,Folkvaljon Y,Robinson D,et al.Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort[J].Eur Urol,2016,69(6):1135-1141.